Last reviewed · How we verify
Anti-PD-1 Therapy
Inhibits PD-1 receptor
Inhibits PD-1 receptor Used for Non-small cell lung cancer, Melanoma, Head and neck cancer.
At a glance
| Generic name | Anti-PD-1 Therapy |
|---|---|
| Also known as | Pembrolizumab |
| Sponsor | Novita Pharmaceuticals, Inc. |
| Drug class | Immune checkpoint inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Anti-PD-1 therapy works by blocking the PD-1 receptor on T cells, allowing them to recognize and attack cancer cells.
Approved indications
- Non-small cell lung cancer
- Melanoma
- Head and neck cancer
Common side effects
- Pneumonitis
- Colitis
- Hypothyroidism
Key clinical trials
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (PHASE2)
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer (PHASE1)
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer (PHASE3)
- Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors (PHASE1, PHASE2)
- A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors (PHASE1, PHASE2)
- Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-PD-1 Therapy CI brief — competitive landscape report
- Anti-PD-1 Therapy updates RSS · CI watch RSS
- Novita Pharmaceuticals, Inc. portfolio CI